Avidicure

Executive Summary

Avidicure is a Netherlands-based biotechnology company pioneering a novel class of triple agonistic antibodies called 'Actibodies'. Its platform is designed to deliver three critical signals to immune effector cells, aiming to sustainably activate the full immune system and overcome limitations of current antibody therapies. The lead program, AVC-S-201, targets γδ T cells for the treatment of acute myeloid leukemia (AML) and other cancers. Founded in 2020 and operating out of Leiden, the company is privately held with no disclosed funding rounds or valuation. Avidicure's approach represents a potentially paradigm-shifting strategy in immuno-oncology by engaging a broader immune response, but the company remains at an early preclinical stage with limited publicly available data. Key upcoming milestones include preclinical proof-of-concept studies, potential IND-enabling activities, and early partnership discussions, which could validate the platform and drive value inflection.

Upcoming Catalysts (preview)

• Q2 2026Preclinical proof-of-concept data for AVC-S-20130% success
• Q4 2026IND-enabling studies initiation25% success
• Q1 2027Strategic partnership or collaboration announcement20% success